NCT03735966View on ClinicalTrials.gov

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

November 20, 2018

Primary Completion Date

October 20, 2020

Study Completion Date

October 20, 2020

Conditions
HER2 Positive Breast Cancer
Interventions
DRUG

Pyrotinib plus trastuzumab and docetaxel and carboplatin

pyrotinib: 320mg orally daily，6cycles; trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6cycles; docetaxel:after the biological window, 100mg/m2 for a total of 6 cycles carboplatin:d1 ，AUC 6 iv 3-weekly for a total of 6 cycles

Trial Locations (1)

Unknown

Henan cancer hospital, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV

NCT03735966 - Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients. | Biotech Hunter | Biotech Hunter